Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Memory Reconsolidation Blockade for Treating Drug Addiction

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01634347
Recruitment Status : Completed
First Posted : July 6, 2012
Last Update Posted : May 15, 2017
Sponsor:
Information provided by (Responsible Party):
Alain Brunet, Ph.D., Douglas Mental Health University Institute

Brief Summary:
The treatment involves administering propranolol, a medication indicated for treating high blood pressure. Propranolol is hypothesized to reduce the strength of drug or alcohol cravings (an integral factor involved in relapse), specifically when memories of substance use are recalled. In this study, propranolol or a placebo will be administered to patients participating in a drug or alcohol rehabilitation facility once a week over three or six weeks. After receiving propranolol or placebo, strong memories associated with substance craving are recalled by asking participants to read aloud a summary of a substance use experience. The investigators hypothesize that participants who receive propranolol will report fewer and less intense drug or alcohol cravings than participants who receive the placebo or treatment-as-usual.

Condition or disease Intervention/treatment Phase
Substance Dependence Drug: Propranolol and memory reactivation Drug: Placebo and memory reactivation Phase 2

Detailed Description:

Trial Objectives: To test the feasibility of reconsolidation blockade as an adjunct treatment for reducing drug or alcohol cravings in individuals diagnosed with a substance dependence or substance abuse disorder and participating in a drug rehabilitation program.

Study Design and Duration: This study will be a 3 to 6 week, randomized, double-blind trial involving participants with a DSM-IV-TR diagnosis of substance dependence or abuse. Consented participants meeting enrolment criteria will receive a dose of propranolol (1mg/kg) or placebo ninety minutes before undergoing a brief memory reactivation procedure twice a week for a three-week period (or once a week for a six week period, depending on the participants availability) as an adjunct to their usual drug rehabilitation treatment. Participants will be randomized to one of two treatment arms (i.e. placebo group + treatment as usual, or propranolol group + treatment as usual) and remain in that arm for the duration of the study. Participants from the placebo arm will be offered the opportunity to continue receive open-label propranolol treatment for another 3-6 weeks following the double-blind phase of the study. A four-month follow-up assessment will also be conducted.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 17 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Memory Reconsolidation Blockade for Treating Drug Addiction: a Feasibility Study
Study Start Date : January 2012
Actual Primary Completion Date : May 2014
Actual Study Completion Date : May 2014

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Memory

Arm Intervention/treatment
Experimental: Propranolol and memory reactivation Drug: Propranolol and memory reactivation
Propranolol will be administered once a week for a 3 or 6 week period. Each propranolol administration will be followed by memory reactivation.

Placebo Comparator: Placebo and memory reactivation Drug: Placebo and memory reactivation
Placebo will be administered once a week for a 3 or 6 week period. Each placebo administration will be followed by memory reactivation.




Primary Outcome Measures :
  1. Substance craving scales [ Time Frame: Weeks 3 or 6 ]
    The craving scales ask about current craving for substances. Items for the questionnaires represent distinct conceptualizations of substance craving: (1) desire to use; (2) anticipation of positive outcomes from use; (3) anticipation of relief from withdrawal symptoms or relief from negative mood; (4) intention and planning to use; (5) lack of control over use.


Secondary Outcome Measures :
  1. Number of days in a drug or alcohol addiction rehabilitation treatment program [ Time Frame: Once or twice a week for a 3-to-6 week period, as well as at 4 months post-baseline ]
  2. Addiction severity [ Time Frame: Once or twice a week for a 3-to-6 week period, as well as at 4 months post-baseline ]
  3. Rates of successfully completing a drug or alcohol rehabilitation program [ Time Frame: Once or twice a week for a 3-to-6 week period, as well as at 4 months post-baseline ]
  4. Rates of planned or unplanned departure and expulsion from a drug or alcohol rehabilitation program [ Time Frame: Once or twice a week for a 3-to-6 week period, as well as at 4 months post-baseline ]
  5. Frequency and intensity of drug or alcohol cravings [ Time Frame: Once or twice a week for a 3-to-6 week period ]
  6. Brief psychiatric rating scale [ Time Frame: Once or twice a week for a 3-to-6 week period, as well as at 4 months post-baseline ]
  7. Rates of relapse of drug or alcohol dependence a drug or alcohol rehabilitation program. [ Time Frame: Once or twice a week for a 3-to-6 week period, as well as at 4 months post-baseline ]
  8. Rates of adverse events [ Time Frame: From baseline to 28 days after the last administration of study medication ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Male or female subjects between 18 and 65 years of age
  • Female subjects must not be of child bearing potential or be non pregnant and be established on an acceptable method of birth control or be one who abstains from sex
  • Diagnosis of substance dependence or substance abuse disorder within a 1-month period prior to screening
  • Currently enrolled in a drug rehabilitation treatment program for marijuana, cocaine, heroin, other opiates, benzodiazepine, alcohol, or amphetamine addictions
  • Individuals who consent to remain abstinent from all drugs of abuse (except nicotine) and from alcohol for 24 hours prior to enrolment and for the duration of the study
  • Individuals treated with the following medications must be on stable doses for at least 1-month prior to the screening visit and during the entire study: anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics
  • Individuals taking Selective Serotonin Reuptake Inhibitors (SSRIs) or Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs) must accept to skip their morning dose the day of each study visit
  • Individuals shall not start taking new medications on a regular basis during the study
  • Fluency in French or English

Exclusion Criteria:

  • Systolic blood pressure <100 mm Hg
  • Cardiac rhythm below 55 beats per minute
  • A medical condition that contraindicates the administration of propranolol
  • Previous adverse reaction to, or non-compliance with, beta-blocker
  • Current use of medication that may involve potentially dangerous interactions with propranolol.
  • Women who are pregnant or breast feeding
  • Past or present bipolar disorder or psychosis
  • Individuals with current dependence on any substance besides, cocaine, heroin, other opiates, benzodiazepines, amphetamines, marijuana, or alcohol
  • Subjects judged as being at significant risk of self injurious/suicidal or violent/homicidal behavior
  • Participation in another drug trial within 30 days prior to the screening visit or during the study
  • Any condition that can significantly affect the absorption of the study medication
  • Presence of any clinical condition that might interfere with the interpretation of the efficacy and safety results

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01634347


Locations
Layout table for location information
Canada, Quebec
The Heritage Home Drug and Alcohol Rehabilitation Centre
Godmanchester, Quebec, Canada, J0S 1H0
Douglas Mental Health University Institute
Montreal, Quebec, Canada, H4H 1R3
Sponsors and Collaborators
Douglas Mental Health University Institute

Additional Information:
Layout table for additonal information
Responsible Party: Alain Brunet, Ph.D., Sponsor-Investigator, Douglas Mental Health University Institute
ClinicalTrials.gov Identifier: NCT01634347    
Other Study ID Numbers: PRPL-004
First Posted: July 6, 2012    Key Record Dates
Last Update Posted: May 15, 2017
Last Verified: May 2017
Additional relevant MeSH terms:
Layout table for MeSH terms
Substance-Related Disorders
Chemically-Induced Disorders
Mental Disorders
Propranolol
Adrenergic beta-Antagonists
Adrenergic Antagonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Anti-Arrhythmia Agents
Antihypertensive Agents
Vasodilator Agents